A Single Center Treatment Experience in Autoimmune Hepatitis Patients

Key Findings & Data:Results: Sixty-one out of 66 patients (92.4%) were treated with a combination of azathiopurine (AZA) and corticosteroids; 45 patients (73.8%) had a complete response.

💡

Conclusion & Impact:Alternative treatments are limited but MMF seems to be promising in this regard.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Aim: The aim of the study was to evaluate the efficacy of therapeutic regimens in autoimmune hepatitis (AIH). Methods: Clinical and demographical data of AIH patients including the therapeutic regimens given and the response to treatment were retrospectively evaluated. Results: Sixty-one out of 66 patients (92.4%) were treated with a combination of azathiopurine (AZA) and corticosteroids; 45 patients (73.8%) had a complete response. In 21 patients (34%) on combination therapy the treatment was modified due to nonresponse (16 patients) or side effects (5 patients) and mycophenolate mofetil (MMF) was initiated in 10 patients (16%) as a second line therapy. In MMF group; 8 patients (80%) had complete, 1 patient (10%) had incomplete response and 2 patients had leucopenia but no cessation of treatment. Conclusion: Complete response can not be obtained in approximately one fourth of patients with AZA and corticosteroid combination. Alternative treatments are limited but MMF seems to be promising in this regard.

Özet

Amaç: Bu çalışmada otoimmun hepatit (OİH) tedavi rejimlerinin etkinliğinindeğerlendirilmesi amaçlandı.Yöntem: OİH tanısı ile takip edilen hastaların klinik, demografik verileri,aldıkları tedaviler ve tedavi yanıtları retrospektif olarak değerlendirildi.Bulgular: Çalışmaya dahil edilen 66 hastanın 61’i (%92.4) birinci basamaktedavi rejimi olarak kortikosteroid ve azatiopürin (AZA) kombinasyonualmaktaydı ve 45 hastada (%73.8) tam yanıt gözlendi. Kombinasyon tedavisialan 21 hastada (%34); tedavi yanıtsızlığı (16 hasta) ve yan etkiler (5 hasta)nedeniyle tedavi değişikliğine gidilmiş ve 10 hastada (%16) ikinci basamakrejim olarak mikofenolat mofetil (MMF) tedavisine geçilmiştir. MMF başlananhastaların 8’inde (%80) tam yanıt, 1’inde (%10) inkomplet yanıt saptanmış, 2hastada (%20) lökopeni görülmüş ancak tedaviyi kesmeyi gerektirmemiştir.Sonuç: OİH tedavisinde konvansiyonel tedavi olan AZA + kortikosteroidkombinasyonu ile hastaların yaklaşık dörtte birinde tam yanıtalınamamaktadır. Alternatif tedaviler sınırlı olmakla birlikte MMF bu konudaumut vaat edici görünmektedir.

🔖

Cite This Article

ÖNAL, İ. K., KARAKAN, T., KARATAŞ, A., CİNDORUK, M., DUMLU, Ş., DOĞAN, İ., İBİŞ, M., ARHAN, M., SARGIN, Z. G., SÜTÇÜOĞLU, O., HAGHİGHİ, N. A., YÜCELDİ, S. D., ÖZENİRLER, S. (2022). A Single Center Treatment Experience in Autoimmune Hepatitis Patients. Gazi Medical Journal, Cilt: 28 - Sayı: 3, 174–178. https://ajindex.com/articles/519886

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66. Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver 2016; 10: 177-203. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971-1004.
Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinicolaboratory and histological characteristics. World J Gastroenterol 2015; 21: 60–83.
Vergani D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677–83.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–38.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–76.
Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001; 39: 339 – 41. Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980 – 9. Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergquist A, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45: 457 – 67. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, et al. Review article: autoimmune hepatitis – current management and challenges. Aliment Pharmacol Ther 2013; 38: 887–913.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193–213.
Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010;24:588–92.
Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;